Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.37 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865558 | 0.89 | MAPT (0.37) | TRPV1NPC1RAB9A | |
| SCHEMBL2809795 | 0.88 | MAPT (0.35) | NPC1RAB9A | |
| SCHEMBL13129755 | 0.86 | MAPT (0.35) | NPC1RAB9A | |
| SCHEMBL16927761 | 0.85 | ENPP2 (0.46) | — | |
| SCHEMBL2810097 | 0.85 | MAPT (0.37) | NPC1RAB9A | |
| SCHEMBL2806094 | 0.83 | KEAP1 (0.37) | NPC1RAB9A | |
| SCHEMBL16927711 | 0.79 | CLK2 (0.59) | CLK2DYRK1ACLK4DYRK3CLK1 | |
| SCHEMBL2810678 | 0.78 | ENPP2 (0.40) | TRPV1ROCK2ROCK1 | |
| SCHEMBL2809858 | 0.78 | ENPP2 (0.43) | — | |
| SCHEMBL2806745 | 0.77 | MAPT (0.45) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046842-A2 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240676-A1 | THIAZOLE DERIVATIVES | CCNE2, PKD1, PKD2 | CLK2 2323/4885DYRK1A 3071/4885CLK4 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.